William B. Horne - 18 Mar 2025 Form 4 Insider Report for Alzamend Neuro, Inc. (ALZN)

Role
Director
Signature
/s/ William B. Horne
Issuer symbol
ALZN
Transactions as of
18 Mar 2025
Net transactions value
+$5,452
Form type
4
Filing time
19 Mar 2025, 16:30:09 UTC
Previous filing
02 Jan 2025
Next filing
20 Mar 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALZN Common Stock Options Exercise $600 +10,000 +150% $0.0600 16,666 18 Mar 2025 Direct F1
transaction ALZN Common Stock Purchase $4,852 +5,000 +30% $0.9703 21,666 18 Mar 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALZN Stock Options (Right to Buy) Options Exercise $0 -10,000 -100% $0.000000 0 18 Mar 2025 Common Stock 10,000 $0.0600 Direct F3
holding ALZN Stock Options (Right to Buy) 1,667 18 Mar 2025 Common Stock 1,667 $225.00 Direct F4
holding ALZN Stock Options (Right to Buy) 1,667 18 Mar 2025 Common Stock 1,667 $225.00 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to Rule 16b-3 with shares of common stock received upon the exercise of stock options.
F2 The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $0.9703. The range of purchase prices on the transaction date was $0.9693 to $0.9742 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
F3 The stock options exercised in this transaction were fully vested and exercisable as of the transaction date.
F4 The stock options vest ratably over thirty-six (36) months beginning on the date of grant and are fully vested.
F5 None of these performance-based stock options are vested or exercisable.